

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

## **UPDATE ANNOUNCEMENT ON DISCLOSEABLE TRANSACTION**

References are made to the announcements of TATA Health International Holdings Limited (the “**Company**”) dated 29 June 2021 (the “**First Announcement**”), 10 August 2021, and 30 August 2021 in relation to, among other things, the Investment. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the First Announcement.

The Company has recently been informed that a judgment (the “**Judgment**”) in relation to the Investment was made against the Company in the Enterprise Court of Walloon Brabant, pursuant to which Shang Ying and the Company were ordered as an interim measure to pay Promethera Therapeutics a provisional sum of EUR1,000,000, the costs of the proceedings, and a scheduling fee of EUR165.

The Company is seeking legal advice on the Judgment. On the advice of its Belgian legal counsel, the Company may appeal against the Judgment. The terms of the Judgment confirm that the Judgment is enforceable notwithstanding appeal. The Company will keep its shareholders and investors informed of any material development as and when appropriate.

By order of the Board  
**TATA Health International Holdings Limited**  
**Yang Jun**  
*Chairman*

Hong Kong, 20 October 2021

*As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Yang Jun and Mr. Lai Wenjing; four non-executive Directors, namely, Mr. Lin Zheming, Mr. Lin Jun, Mr. Chu Chun Ho, Dominic and Mr. Chen Anhua and three independent non-executive Directors, namely, Mr. Xie Rongxing, Prof. Yan Haifeng and Ms. Tan Yuying.*